Enrollment commences in Palatin's bremelanotide Phase 2b trial for female sexual dysfunction
Links shared publicly online about this topic.
- 185total visits
Enrollment commences in Palatin's bremelanotide Phase 2b trial for female sexual dysfunction
Palatin Technologies, Inc. announced today that enrollment of patients has commenced in Palatin's Phase 2b clinical trial evaluating the efficacy and safety of bremelanotide (previously called PT-141), an on-demand, first-in-class melanocortin agonist being developed for the treatment of female sexual dysfunction (FSD).
View full resource at news-medical.net
Tags: Sexual Health, Clinical Trial, Sex and Intimacy, Women's Health, Sexual Dysfunction, Safety
Most Recently Shared on June 28, 2011 at 9:28 pm By:
Enrollment commences in Palatin's bremelanotide Phase 2b trial for female sexual dysfunction: Palatin Technologi... http://bit.ly/m5QT6f
Palatin Technologies, Inc. Initiates Enrollment In Phase 2b Trial With Bremelanotide In Women With Female Sexual Dysfunction
medicalnewstoday.com — “Palatin Technologies, Inc. (NYSE Amex: PTN) announced that enrollment of patients has commenced in Palatin's Phase 2b clinical trial evaluating the efficacy and safety of bremelanotide (previously” View full resource at medicalnewstoday.com
Most Recently Shared on June 29, 2011 at 9:31 am By:
Debby Verville Health Advocate
Palatin Technologies, Inc. Initiates Enrollment In Phase 2b Trial With Bremelanotide In Women With Female Sexual... http://bit.ly/iXa3ER
Advertisement
